Monoclonal antibody for resisting antigen of RBD structural domain of novel coronavirus

A monoclonal antibody and coronavirus technology, applied in antiviral agents, antiviral immunoglobulins, antibodies, etc., can solve the problem that there is no new coronavirus RBD domain antigen therapeutic antibody available, and achieve strong anti-new coronavirus ability, strong effect

Active Publication Date: 2020-11-24
SICHUAN UNIV
View PDF6 Cites 19 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There are currently no therapeutic antibodies against the RBD domain antigen of the novel coronavirus available

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Monoclonal antibody for resisting antigen of RBD structural domain of novel coronavirus
  • Monoclonal antibody for resisting antigen of RBD structural domain of novel coronavirus
  • Monoclonal antibody for resisting antigen of RBD structural domain of novel coronavirus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Embodiment 1: the monoclonal antibody preparation and detection of anti-RBD domain antigen

[0024] 1. Preparation of RBD antigen

[0025] The immune antigen used in this experiment for mice is the RBD domain of the SPIKE protein on the surface of the SARS-CoV2 virus. An insect expression system was used. Since it is a secreted protein, the medium supernatant was collected after centrifugation and separated and purified using a nickel column. The purified protein was quantified using 12.5% ​​SDS-PAGE gel (see figure 1 ). The purified protein was then aliquoted and freeze-dried for storage at -80C. (Avoid repeated freezing and thawing to cause protein degradation).

[0026] 2. Immunization of mice with RBD antigen and determination of polyantibody serum titers

[0027] 6-week-old female mice were used. One week before immunization, 200-400ul of blood was collected from the tail vein of the mouse by docking the tail (as a negative control for subsequent experiments);...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a monoclonal antibody for resisting an antigen of a RBD structural domain of novel coronavirus and belongs to the field of biological products. According to the monoclonal antibody disclosed by the invention, an amino acid sequence of a heavy-chain variable region of the monoclonal antibody is represented by any of SEQ ID No. 1-17, and an amino acid sequence of a light-chain variable region of the monoclonal antibody is represented by any of SEQ ID No. 18-34. The monoclonal antibody disclosed by the invention has good ability for preventing RBD of the novel coronavirusfrom bonding with an acceptor of the RBD; and verified by experiments, the coronavirus can be effectively prevented from infecting cells.

Description

technical field [0001] The invention belongs to the field of biological products. Background technique [0002] Pneumonia caused by the novel coronavirus (SARS-CoV2) infection is a major public health problem facing the world today. As of June 24, 2020, the cumulative number of confirmed cases in the world has exceeded 9.2 million; although my country's epidemic prevention and control is relatively good globally, in the context of the general trend of global epidemic spread, the work of moving forward and scientific research are imminent . However, up to now, there is no specific drug for pneumonia caused by SARS-CoV2 virus. Current research has confirmed that the spike glycoprotein (Spike protein) on the surface of the new coronavirus is very close to the antigenicity of SARS in three-dimensional spatial conformation; based on The structural study of the virus found that the receptor binding domain (RBD) on the SARS-CoV2 virus can specifically recognize human angiotensin-c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13C12N15/85C12N5/10A61K39/42A61P31/14
CPCC07K16/10C12N15/85A61P31/14C07K2317/56C07K2317/92C07K2317/76A61K2039/505
Inventor 唐麟
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap